We appreciate Dr Safer et al. 1 letter regarding our article. Although we agree with their point of view regarding the methodological limitations of our study, such as the basis of the exclusion ...
WESTON, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (ZVSA) (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback